Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)
United States68 participantsStarted 2025-07-15
Plain-language summary
The primary objective of this study is to determine if the addition of Rocklatan post-Hydrus will provide additional intraocular pressure lowering.
Who can participate
Age range
40 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age 40 years and older
* Subjects who have mild to moderate Open Angle Glaucoma (OAG)
* Subjects who have undergone uncomplicated cataract surgery and Hydrus microstent implantation \> 3 months prior to screening and within the last 2 years
* Post-Hydrus subjects on 0-2 ocular hypotensive medication classes who can safely washout (if on ocular hypotensive medications)
* Unmedicated or washed out IOP range between 16-26 mmHg
Exclusion Criteria:
* History of intraocular surgery except for uneventful refractive surgery or uncomplicated cataract surgery and hydrus microstent implantation
* Prior Selective Laser Trabeculoplasty (SLT) within 18 months of surgery
* Secondary glaucoma excluding pseudoexfoliation and pigmentary dispersion syndrome
* Severe Open Angle Glaucoma
* Narrow angles, other angle abnormalities or angle closure glaucoma
* Allergy or intolerance to Rocklatan
* History of corneal edema, or corneal disease or dystrophy
* Current or history of intra-ocular infection or inflammation
* History of retinal diseases that could affect diagnostic testing
* Anticipated use of intra-ocular or topical steroids not associated with the study protocol
* Pregnant, breastfeeding or planning to become pregnant during the study
* Any condition in the opinion in the investigator that would potentially confound the results of the study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Mean diurnal intraocular pressure change from baseline
Timeframe: After 28 days up to 35 days post initiation of Rocklatan vs placebo comparator